Replimune Group Stock Forecast, Price & News

Replimune Group (NASDAQ:REPL) Frequently Asked Questions

Is Replimune Group a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Replimune Group stock.
View analyst ratings for Replimune Group or view top-rated stocks.

How has Replimune Group's stock price been impacted by COVID-19?

Replimune Group's stock was trading at $11.93 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, REPL shares have increased by 143.1% and is now trading at $29.00.
View which stocks have been most impacted by COVID-19.

When is Replimune Group's next earnings date?

Replimune Group is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Replimune Group.

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.51) by $0.05.
View Replimune Group's earnings history.

What price target have analysts set for REPL?

4 equities research analysts have issued 12-month target prices for Replimune Group's shares. Their forecasts range from $49.00 to $60.00. On average, they anticipate Replimune Group's share price to reach $55.00 in the next year. This suggests a possible upside of 89.7% from the stock's current price.
View analysts' price targets for Replimune Group or view top-rated stocks among Wall Street analysts.

Who are Replimune Group's key executives?

Replimune Group's management team includes the following people:

• Philip Astley-Sparke, Chief Executive Officer & Director
• Robert Coffin, President & Director
• Colin A. Love, Chief Operating Officer (LinkedIn Profile)
• Jean M. Franchi, Chief Financial Officer, Secretary & Treasurer
• Pamela Esposito, Chief Business Officer (LinkedIn Profile)

Who are some of Replimune Group's key competitors?

Some companies that are related to Replimune Group include Exelixis (EXEL), Beam Therapeutics (BEAM), Abcam (ABCM), Fate Therapeutics (FATE), Kodiak Sciences (KOD), Halozyme Therapeutics (HALO), Vir Biotechnology (VIR), Twist Bioscience (TWST), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Sana Biotechnology (SANA), SpringWorks Therapeutics (SWTX), Relay Therapeutics (RLAY), Recursion Pharmaceuticals (RXRX) and Valneva (VALN).
View all of REPL's competitors.

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.47%), Ensign Peak Advisors Inc (2.75%), Emerald Mutual Fund Advisers Trust (2.17%), BVF Inc. IL (1.98%), Emerald Advisers LLC (1.97%) and Victory Capital Management Inc. (1.78%). Company insiders that own Replimune Group stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke and Robert Coffin.
View institutional ownership trends for Replimune Group.

Which major investors are selling Replimune Group stock?

REPL stock was sold by a variety of institutional investors in the last quarter, including Ensign Peak Advisors Inc, Invesco Ltd., Victory Capital Management Inc., Citigroup Inc., Two Sigma Investments LP, Two Sigma Advisers LP, Morgan Stanley, and Millennium Management LLC. Company insiders that have sold Replimune Group company stock in the last year include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke, and Robert Coffin.
View insider buying and selling activity for Replimune Group or view top insider-selling stocks.

Which major investors are buying Replimune Group stock?

REPL stock was bought by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Dimensional Fund Advisors LP, BlackRock Inc., Candriam Luxembourg S.C.A., Geode Capital Management LLC, Goldman Sachs Group Inc., and UBS Group AG.
View insider buying and selling activity for Replimune Group or or view top insider-buying stocks.

How do I buy shares of Replimune Group?

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $29.00.

How much money does Replimune Group make?

Replimune Group has a market capitalization of $1.36 billion. The company earns $-80.87 million in net income (profit) each year or ($1.94) on an earnings per share basis.

How many employees does Replimune Group have?

Replimune Group employs 152 workers across the globe.

What is Replimune Group's official website?

The official website for Replimune Group is www.replimune.com.

Where are Replimune Group's headquarters?

Replimune Group is headquartered at 500 Unicorn Park, WOBURN MA, 01801.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at (781) 222-9600 or via email at [email protected].